Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors.

Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.

Eighty-seven cats with histologically confirmed malignant tumors were used in a prospective study to determine the toxicity of mitoxantrone, a dihydroxyquinone derivative of anthracene, which was administered at 21-day intervals at dosages ranging from 2.5 to 6.5 mg/m2 of body surface, IV.

Nutritional management of cats with infectious disease.

The effect of malnutrition in patients with a variety of ailments is known to be deleterious to their overall quality of life, response and tolerance to therapy, and ultimate survival. These effects may be amplified in feline patients with infectious disease owing to the blunting of immunologic responsiveness that results from malnutrition. This vicious cycle of infection, ensuing malnutrition, and subsequent immunocompromise may not allow the patient to mount an attack on the invading pathogen adequately.

Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

The protective effect of methimazole, a commonly used antithyroid drug, on cisplatin-induced nephrotoxicity was studied. Eight dogs received 80 mg/m2 cisplatin i.v.

Effects of chemotherapy and remission on carbohydrate metabolism in dogs with lymphoma.

After a 12-hour fast, blood samples were obtained from 27 dogs with previously untreated lymphoma before and 5, 15, 30, 45, and 60 minutes after an intravenous (IV) challenge with 500 mg/kg dextrose. This procedure was done for each dog before up to five treatments with the IV doxorubicin (30 mg/m2 every 3 weeks). All dogs achieved a complete remission.

Amputation and cisplatin for treatment of canine osteosarcoma.

Seventy-one dogs with histologically confirmed appendicular osteosarcoma were evaluated. Seventeen dogs were treated with amputation and two postoperative [corrected] doses of IV cisplatin given 21 days apart (group 1). Nineteen dogs were treated with IV cisplatin 21 days before amputation, with a second dose given immediately after amputation (group 2).

Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.

Nine dogs with intermediate- or high-grade lymphoma were prospectively entered into a protocol to be given a total of 15 weekly doses of doxorubicin (10 mg/m2 of body surface, IV) in an attempt to eliminate all clinical evidence of neoplasia, with minimal risk of drug toxicity. Eight of these dogs did not complete the protocol because of progression of the disease. The median number of doses administered to dogs that developed progressive disease before the regimen was completed was 5 (range, 2 to 9).

Efficacy of mitoxantrone against various neoplasms in dogs.

One hundred twenty-six dogs with histologically confirmed, measurable malignant tumors were evaluated in a prospective study to determine the response to the antineoplastic drug mitoxantrone. Ninety-five dogs had been refractory to one or more treatment modalities (surgery, n = 57; chemotherapy other than mitoxantrone, n = 37; radiation, n = 4; whole body hyperthermia, n = 1). The extent of neoplastic disease was determined immediately before each dose of mitoxantrone was administered (1 to 10 doses, 2.

Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.

One hundred twenty-nine dogs with histologically confirmed malignant tumors were used in a prospective study to determine the toxicity of the new dihydroxyquinone derivative of anthracene, mitoxantrone, which was administered IV at 21-day intervals at dosages ranging from 2.5 to 5 mg/m2 body surface area. Each dog was evaluated for signs of toxicosis for 3 weeks after each dose was administered or until the dog died, whichever came first.

Exacerbation of hyperlactatemia by infusion of lactated Ringer's solution in dogs with lymphoma.

Blood lactate concentrations and acid-base status of six dogs with lymphoma were compared statistically with those from six healthy control dogs before, during, and after a 6-hour infusion of lactated Ringer's solution (LRS). Blood lactate concentrations in dogs with lymphoma were significantly (P less than 0.05) higher immediately before, and at the 1-, 2-, 4-, and 6-hour time periods after infusion when compared with controls.

Nutrition and cancer. Recent developments.

Cancer cachexia is a complex syndrome that results in involuntary weight loss, even in the face of adequate nutritional intake. The profound metabolic abnormalities associated with cancer cachexia affect a large percentage of animals with cancer even before any clinical signs are seen. This paraneoplastic syndrome results in alterations in carbohydrate, lipid, and protein metabolism that, if left untreated, decrease the animal's quality of life and lead to a poor response to cancer therapy.

Alterations in carbohydrate metabolism in canine lymphoma.

Following an overnight fast, blood samples were obtained from 14 dogs with previously untreated lymphoma before and 5, 15, 30, 45, 60, and 90 minutes following an intravenous challenge with 500 mg/kg dextrose. Samples were assayed for glucose, lactate, and insulin concentrations and compared statistically with ten control dogs of similar weight and age undergoing an identical dextrose challenge. Dogs with lymphoma had similar glucose tolerance curves when compared with controls.

Applicability of leukocyte esterase test strip in detection of canine pyuria.

A commercially available leukocyte esterase assay was evaluated for application in analyzing canine urine for the detection of pyuria. In 229 urine samples, the leukocyte esterase activity was compared with leukocyte concentrations, as assessed by microscopic sediment analysis and chamber cell counts. The leukocyte esterase assay was specific (93.